PE20120110A1 - [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa - Google Patents
[1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasaInfo
- Publication number
- PE20120110A1 PE20120110A1 PE2011001470A PE2011001470A PE20120110A1 PE 20120110 A1 PE20120110 A1 PE 20120110A1 PE 2011001470 A PE2011001470 A PE 2011001470A PE 2011001470 A PE2011001470 A PE 2011001470A PE 20120110 A1 PE20120110 A1 PE 20120110A1
- Authority
- PE
- Peru
- Prior art keywords
- triazolo
- pyridines
- kinase inhibitors
- phenylamine
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE [1,2,4]TRIAZOLO[1,5-a]PIRIDINAS DE FORMULA (I) DONDE A1 Y A2 SON CADA UNO N O C; R1 Y R2 SON CADA UNO H, ALQUILO(C1-C4), ARILO, HALOGENO, ENTRE OTROS; R3 ES H, ALQUILO(C1-C4), CICLOALQUILO, ARILO, CN, ENTRE OTROS; X ES UN ENLACE O (CH2)aW(CH2)b, (CH2)aW(CH2)bY(CH2)c, ENTRE OTROS, EN DONDE a, b Y c SON CADA UNO DE 0 A 3; W E Y SON CADA UNO -CO-, -O-, -SO2-, -CH2-, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: CLORHIDRATO DE 4-CLORO-3-{2-[4-(2-PIRROLIDIN-1-IL-ETOXI)-FENILAMINO]-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL}-FENOL; CLORHIDRATO DE 4-CLORO-3-{8-METIL-2-[4-(2-PIRROLIDIN-1-IL-ETOXI)-FENILAMINO]-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL}-FENOL; 4-CLORO-3-{2-[4-(2-MORFOLIN-4-IL-ETOXI)-FENILAMINO]-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL}-FENOL; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE CINASA SIENDO UTILES EN EL TRATAMIENTO DE INFARTO DE MIOCARDIO, CANCER, ARTRITIS, RETINOPATIA, GLAUCOMA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09360013 | 2009-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120110A1 true PE20120110A1 (es) | 2012-02-20 |
Family
ID=42229029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001470A PE20120110A1 (es) | 2009-02-13 | 2010-02-09 | [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa |
Country Status (24)
Country | Link |
---|---|
US (1) | US20120041195A1 (es) |
EP (1) | EP2396324A1 (es) |
JP (1) | JP2012517971A (es) |
KR (1) | KR20110116160A (es) |
CN (1) | CN102317288A (es) |
AR (1) | AR075411A1 (es) |
BR (1) | BRPI1008850A2 (es) |
CA (1) | CA2751517A1 (es) |
CL (1) | CL2011001947A1 (es) |
CO (1) | CO6420343A2 (es) |
CR (1) | CR20110386A (es) |
DO (1) | DOP2011000248A (es) |
EA (1) | EA201101188A1 (es) |
EC (1) | ECSP11011250A (es) |
HN (1) | HN2011002095A (es) |
IL (1) | IL214426A0 (es) |
MX (1) | MX2011008549A (es) |
NI (1) | NI201100151A (es) |
NZ (1) | NZ594508A (es) |
PE (1) | PE20120110A1 (es) |
SG (1) | SG173610A1 (es) |
TN (1) | TN2011000379A1 (es) |
WO (1) | WO2010092041A1 (es) |
ZA (1) | ZA201105896B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8501936B2 (en) | 2009-06-05 | 2013-08-06 | Cephalon, Inc. | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
EP2343295A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
TW201204723A (en) * | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
US20140120087A1 (en) * | 2011-04-21 | 2014-05-01 | Bayer Intellectual Property Gmbh | Triazolopyridines |
WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
UA112096C2 (uk) | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
KR20130091464A (ko) | 2012-02-08 | 2013-08-19 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체 |
ES2605946T3 (es) | 2012-03-14 | 2017-03-17 | Bayer Intellectual Property Gmbh | Imidazopiridazinas sustituidas |
IN2015DN00085A (es) | 2012-07-10 | 2015-05-29 | Bayer Pharma AG | |
WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
CN105377848A (zh) | 2013-06-11 | 2016-03-02 | 拜耳制药股份公司 | 取代的三唑并吡啶的前体药物衍生物 |
EP4063371A1 (en) * | 2019-11-22 | 2022-09-28 | Medshine Discovery Inc. | Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6056684B2 (ja) | 1977-11-07 | 1985-12-11 | 東興薬品工業株式会社 | 点眼剤 |
US4271143A (en) | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
US4407792A (en) | 1979-05-09 | 1983-10-04 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
ATE151286T1 (de) | 1983-11-14 | 1997-04-15 | Columbia Lab Inc | Bioadhäsive mittel |
US5041434A (en) | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
WO2001038315A1 (en) | 1999-11-22 | 2001-05-31 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
US7268136B2 (en) * | 2002-12-18 | 2007-09-11 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての2−アミノピリジン置換ヘテロ環類 |
CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
KR20070029110A (ko) | 2003-10-16 | 2007-03-13 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 암의 치료를 위한 raf 키나아제의 저해제로서2,6-디치환 퀴나졸린, 퀴녹살린, 퀴놀린 및 아이소퀴놀린 |
KR20070011458A (ko) | 2004-04-08 | 2007-01-24 | 탈자진 인코포레이티드 | 키나제의 벤조트리아진 억제제 |
MX2007002208A (es) | 2004-08-25 | 2007-05-08 | Targegen Inc | Compuestos hetrociclicos y metodos de uso. |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
WO2006101977A2 (en) | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
JP5079500B2 (ja) | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | 2−アミノキナゾリン誘導体 |
MX2007008848A (es) | 2005-06-08 | 2008-04-16 | Targegen Inc | Metodos y composiciones para el tratamiento de desordenes oculares. |
US20070129364A1 (en) * | 2005-12-07 | 2007-06-07 | Han-Qing Dong | Pyrrolopyridine kinase inhibiting compounds |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
JP5336375B2 (ja) * | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
BRPI0718162A2 (pt) * | 2006-10-20 | 2013-11-26 | Irm Llc | Composição e métodos para modulara os receptores c-kit e pdgfr |
TW200829566A (en) | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
EP2125755A2 (en) | 2006-12-22 | 2009-12-02 | Novartis Ag | Quinazolines for pdk1 inhibition |
GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
MX2010014005A (es) * | 2008-06-20 | 2011-02-15 | Genentech Inc | Compuestos de triazolopiridina inhibidores de jak y los metodos. |
KR20110031475A (ko) * | 2008-06-20 | 2011-03-28 | 제넨테크, 인크. | 트리아졸로피리딘 jak 억제제 화합물 및 방법 |
WO2010010189A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
WO2010010184A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
WO2010010188A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
WO2010018874A1 (en) * | 2008-08-12 | 2010-02-18 | Takeda Pharmaceutical Company Limited | Amide compound |
TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
-
2010
- 2010-02-09 CA CA2751517A patent/CA2751517A1/en not_active Abandoned
- 2010-02-09 MX MX2011008549A patent/MX2011008549A/es not_active Application Discontinuation
- 2010-02-09 JP JP2011549537A patent/JP2012517971A/ja active Pending
- 2010-02-09 NZ NZ594508A patent/NZ594508A/en not_active IP Right Cessation
- 2010-02-09 CN CN2010800077376A patent/CN102317288A/zh active Pending
- 2010-02-09 BR BRPI1008850A patent/BRPI1008850A2/pt not_active IP Right Cessation
- 2010-02-09 KR KR1020117018592A patent/KR20110116160A/ko not_active Application Discontinuation
- 2010-02-09 WO PCT/EP2010/051556 patent/WO2010092041A1/en active Application Filing
- 2010-02-09 EA EA201101188A patent/EA201101188A1/ru unknown
- 2010-02-09 PE PE2011001470A patent/PE20120110A1/es not_active Application Discontinuation
- 2010-02-09 SG SG2011057247A patent/SG173610A1/en unknown
- 2010-02-09 US US13/201,165 patent/US20120041195A1/en not_active Abandoned
- 2010-02-09 EP EP10706180A patent/EP2396324A1/en not_active Withdrawn
- 2010-02-12 AR ARP100100400A patent/AR075411A1/es not_active Application Discontinuation
-
2011
- 2011-07-15 CR CR20110386A patent/CR20110386A/es unknown
- 2011-07-28 NI NI201100151A patent/NI201100151A/es unknown
- 2011-07-29 HN HN2011002095A patent/HN2011002095A/es unknown
- 2011-07-29 DO DO2011000248A patent/DOP2011000248A/es unknown
- 2011-08-03 IL IL214426A patent/IL214426A0/en unknown
- 2011-08-03 TN TN2011000379A patent/TN2011000379A1/fr unknown
- 2011-08-09 EC EC2011011250A patent/ECSP11011250A/es unknown
- 2011-08-11 ZA ZA2011/05896A patent/ZA201105896B/en unknown
- 2011-08-11 CO CO11102097A patent/CO6420343A2/es not_active Application Discontinuation
- 2011-08-11 CL CL2011001947A patent/CL2011001947A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP11011250A (es) | 2011-10-31 |
US20120041195A1 (en) | 2012-02-16 |
MX2011008549A (es) | 2011-12-06 |
KR20110116160A (ko) | 2011-10-25 |
JP2012517971A (ja) | 2012-08-09 |
CN102317288A (zh) | 2012-01-11 |
IL214426A0 (en) | 2011-09-27 |
CO6420343A2 (es) | 2012-04-16 |
EA201101188A1 (ru) | 2012-04-30 |
NI201100151A (es) | 2012-10-03 |
BRPI1008850A2 (pt) | 2016-03-15 |
EP2396324A1 (en) | 2011-12-21 |
AR075411A1 (es) | 2011-03-30 |
TN2011000379A1 (en) | 2013-03-27 |
DOP2011000248A (es) | 2011-10-31 |
HN2011002095A (es) | 2014-01-06 |
CA2751517A1 (en) | 2010-08-19 |
SG173610A1 (en) | 2011-09-29 |
ZA201105896B (en) | 2012-03-28 |
WO2010092041A1 (en) | 2010-08-19 |
CL2011001947A1 (es) | 2012-03-16 |
NZ594508A (en) | 2013-12-20 |
CR20110386A (es) | 2011-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120110A1 (es) | [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa | |
PE20140927A1 (es) | Compuestos heterociclicos como inhibidores de cinasas | |
PE20121158A1 (es) | Derivados de feniletinilo como moduladores alostericos positivos (map) | |
PE20141973A1 (es) | Compuestos de heterociclilo como inhibidores de mek | |
PE20091039A1 (es) | IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10 | |
PE20140928A1 (es) | Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas | |
UY31126A1 (es) | Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus | |
PE20121438A1 (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a | |
PE20121482A1 (es) | Derivados de imidazopiridina como inhibidores de jak | |
CR20140099A (es) | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar | |
PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
MX2009010728A (es) | Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. | |
PE20141283A1 (es) | Nuevos derivados biciclicos de dihidroisoquinolin-1-ona | |
CU24083B1 (es) | Derivados de oxazina útiles como inhibidores de bace para el tratamiento de trastornos neurológicos | |
PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
PE20050691A1 (es) | Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa | |
PE20091833A1 (es) | Derivados heterociclicos espiro biciclicos o heterociclicos biciclicos, puenteados, de pirazolo [1,5-a]pirimidinas como inhibidores de quinasas raf y metodos para su preparacion | |
PE20140390A1 (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak | |
AR082154A1 (es) | DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA COMO MODULADORES DE IRAK4 | |
PE20120534A1 (es) | PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt | |
PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
PE20121148A1 (es) | Compuestos heterociclicos y usos de los mismos | |
PE20120493A1 (es) | Pirimidinonas como inhibidores de pi3k | |
ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |